telcagepant potassium
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 15, 2007 (NCT00442936)
Timeline
Indications
Studied for
Mechanism of action
- Calcitonin gene-related peptide 1INHIBITOR
CALCA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCO.O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c([O-])nc3ncccc32)CC1.[K+]- Mol. weight
- 650.69 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105656 ↗
Also known as
- telcagepant potassium
- telcagepant potassium
- telcagepant potassium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00701389 | Phase 1 | Nov 20, 2007 | Merck |
| NCT01209741 | Phase 1 | Oct 1, 2007 | Merck |
| NCT00442936 | Phase 3 | Feb 15, 2007 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 2 | 2007 |
1 organizations
Page 1 / 1